Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

The Lancet Respiratory Medicine

Volumn 4, Issue 9, 2016, Pages 708-719

  Tashkin, Donald P ^a   Roth, Michael D ^a   Clements, Philip J ^a   Furst, Daniel E ^a   Khanna, Dinesh ^d   Kleerup, Eric C ^a   Goldin, Jonathan ^b   Arriola, Edgar ^c   Volkmann, Elizabeth R ^a   Kafaja, Suzanne ^a   Silver, Richard ^e   Steen, Virginia ^f   Strange, Charlie ^e   Wise, Robert ^g   Wigley, Fredrick ^g   Mayes, Maureen ^h   Riley, David J ⁱ   Hussain, Sabiha ⁱ   Assassi, Shervin ^h   Hsu, Vivien M ⁱ   Patel, Bela ^h   Phillips, Kristine ^d   Martinez, Fernando ^d   Golden, Jeffrey ^j   Connolly, M Kari ^j   Varga, John ^k   Dematte, Jane ^k   Hinchcliff, Monique E ^k   Fischer, Aryeh ^l   Swigris, Jeffrey ^l   Meehan, Richard ^l   Theodore, Arthur ^m   Simms, Robert ^m   Volkov, Suncica ⁿ   Schraufnagel, Dean E ⁿ   Scholand, Mary Beth ^o   Frech, Tracy ^o   Molitor, Jerry A ^p   Highland, Kristin ^e   Read, Charles A ^f   Fritzler, Marvin J ^q   Kim, Grace Hyun J ^b   Tseng, Chi Hong ^a   Elashoff, Robert M ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁱ ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l DEPARTMENT OF MEDICINE   (United States)

^m BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF ILLINOIS   (United States)

^o UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^q UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; HEMOGLOBIN; MYCOPHENOLATE MOFETIL; PLACEBO; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AGED; ALVEOLAR VOLUME RATIO; ANEMIA; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DIFFUSING CAPACITY OF THE LUNG FOR CARBON MONOXIDE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EVENING DOSAGE; FEMALE; FORCED VITAL CAPACITY; FUNDING; GEL; HEMATURIA; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LONGITUDINAL STUDY; LUNG FUNCTION; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; MODIFIED RODNAN SKIN SCORE; MORBIDITY; MORNING DOSAGE; MORTALITY; MULTIPLE SCLEROSIS; NEUTROPENIA; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT PARAMETERS; SCLERODERMA; SCLERODERMA RELATED INTERSTITIAL LUNG DISEASE; SKIN THICKNESS SCORE; SURVIVAL RATE; THROMBOCYTOPENIA; TRANSITION DYSPNEA INDEX; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNITED STATES; CLINICAL TRIAL; COMPLICATION; DISEASE EXACERBATION; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ADULT; AGED; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84989846173     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30152-7     Document Type: Article

References (29)

1. 1 Tyndall, AJ, Bannert, B, Vonk, M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69 (2010), 1809–1815.
2. 2 Nihtyanova, S, Schreiber, BE, Ong, VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 66 (2014), 1625–1635.
3. 3 Tashkin, DP, Elashoff, R, Clements, PJ, et al., Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 (2006), 2655–2666.
4. 4 Goldin, J, Elashoff, R, Kim, HJ, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 136 (2009), 1333–1340.
5. 5 Kim, HJ, Brown, MS, Elashoff, R, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosophamide. Eur Radiol 21 (2011), 2455–2465.
6. 6 Tashkin, DP, Elashoff, R, Clements, PJ, et al., for the Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 (2007), 1026–1034.
7. 7 Furst, DE, Tseng, CH, Clements, PJ, et al., for the Scleroderma Lung Study. Adverse events during the Scleroderma Lung Study. Am J Med 124 (2011), 459–467.
8. 8 Martinez, FJ, McCune, JW, Cyclophosphamide for scleroderma lung disease. N Engl J Med 354 (2006), 2707–2709.
9. 9 Staatz, CE, Tett, SE, Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol 88 (2014), 1351–1389.
10. 10 Hahn, BH, McMahon, MA, Wilkinson, A, et al. American college of rheumatology guidelines for screening, treatment and management of lupus nephritis. Arthritis Care Res 64 (2012), 797–808.
11. 11 Nihtyanova, SI, Brough, GM, Black, CM, Denton, CP, Mycophenolate mofetil in diffuse cutaneous systemic sclerosis–a retrospective analysis. Rheumatology (Oxford) 46 (2007), 442–445.
12. 12 Gerbino, AJ, Goss, CH, Molitor, JA, Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133 (2008), 455–460.
13. 13 Swigris, JJ, Olson, AL, Fischer, A, et al. Mycophenolate mofetil is safe, well tolerated and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130 (2006), 30–36.
14. 14 Zamora, AC, Wolters, PJ, Collard, HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102 (2008), 150–155.
15. 15 Simeón-Aznar, CP, Fonollosa-Plá, V, Tolosa-Vilella, C, et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol, 30, 2011, 1393.
16. 16 Fischer, A, Brown, KK, DuBois, RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40 (2013), 640–646.
17. 17 Masi, T Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic, Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheumatol 23 (1980), 581–590.
18. 18 Mahler, DA, Weinberg, DH, Wells, CK, Feinstein, AR, The measurement of dyspnea. Contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest 85 (1984), 751–758.
19. 19 Clements, PJ, Lachenbruch, PA, Seibold, JR, et al. Skin thickness score in systemic sclerosis (SSc): An assessment of inter-observer variability in three independent studies. J Rheumatol 20 (1993), 1892–1896.
20. 20 Mahler, DA, Ward, J, Fierro-Carrion, G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD 1 (2004), 165–172.
21. 21 Kim, HJ, Tashkin, DP, Clements, PJ, et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol 5 (2010), S26–S35.
22. 22 Roth, MD, Tseng, CH, Clements, PJ, et al., Scleroderma Lung Study Research Group. Predicting lung function and treatment outcomes in scleroderma-related interstitial lung disease. Arthritis Rheum 63 (2011), 2797–2808.
23. 23 Li, N, Elashoff, RM, Li, G, Tseng, CH, Joint analysis of bivariate longitudinal ordinal outcomes and competing risks survival times with nonparametric distributions for random effects. Stat Med 31 (2012), 1707–1721.
24. 24 Elashoff, RM, Li, G, Li, N, A joint model for longitudinal measurements and survival data in the presence of multiple failure types. Biometrics 64 (2008), 762–771.
25. 25 Tashkin, DP, Volkmann, ER, Tseng, CH, et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis 75 (2016), 374–381.
26. 26 Khanna, D, Furst, DE, Hays, RD, et al. Minimally important difference in diffuse systemic sclerosis: results of the D-penicillamine study. Ann Rheum Dis 65 (2006), 1325–1329.
27. 27 Khanna, D, Tseng, CH, Furst, DE, et al. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial—results from the Scleroderma Lung Study. Rheumatology (Oxford) 48 (2009), 1537–1540.
28. 28 Zheng, Y, Li, M, Zhang, Y, Shi, X, Li, L, Jin, M, The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats. Rheumatol Int 30 (2010), 341–348.
29. 29 Saketkoo, LA, Lammi, MR, Fischer, A, Molitor, J, Steen, VD, on behalf of the PHAROS Investigators. Observations from the pulmonary hypertension recognition and outcomes in scleroderma (Pharos) Cohort. Ann Rheum Dis, 74, 2015, 820 (abstr).